Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 848 entries
Sorted by: Best Match Show Resources per page
Esophageal metastasis of renal cancer 10 years after nephrectomy.

Esophagus : official journal of the Japan Esophageal Society

Izumo W, Ota M, Narumiya K, Shirai Y, Kudo K, Yamamoto M.
PMID: 25620904
Esophagus. 2015;12:91-94. doi: 10.1007/s10388-013-0411-7. Epub 2014 Jan 08.

The patient was a 65-year-old man, who had undergone right nephrectomy for renal cancer in 2002. At that time, histopathological examination revealed clear cell carcinoma (pT3a, pN0, M0, and pStage III). Postoperatively, he received natural interferon alpha (6 million...

Cite
Izumo W, Ota M, Narumiya K, et al. Esophageal metastasis of renal cancer 10 years after nephrectomy. Esophagus. 2014;12:91-94doi: 10.1007/s10388-013-0411-7.
Izumo, W., Ota, M., Narumiya, K., Shirai, Y., Kudo, K., & Yamamoto, M. (2015). Esophageal metastasis of renal cancer 10 years after nephrectomy. Esophagus : official journal of the Japan Esophageal Society, 1291-94. https://doi.org/10.1007/s10388-013-0411-7
Izumo, Wataru, et al. "Esophageal metastasis of renal cancer 10 years after nephrectomy." Esophagus : official journal of the Japan Esophageal Society vol. 12 (2015): 91-94. doi: https://doi.org/10.1007/s10388-013-0411-7
Izumo W, Ota M, Narumiya K, Shirai Y, Kudo K, Yamamoto M. Esophageal metastasis of renal cancer 10 years after nephrectomy. Esophagus. 2015;12:91-94. doi: 10.1007/s10388-013-0411-7. Epub 2014 Jan 08. PMID: 25620904; PMCID: PMC4297612.
Copy Download .nbib Format: NLM
Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B.

Journal of clinical and translational hepatology

Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X, Ren H.
PMID: 29577026
J Clin Transl Hepatol. 2018 Mar 28;6(1):1-10. doi: 10.14218/JCTH.2017.00073. Epub 2018 Mar 17.

No abstract available.

Cite
Zhang W, Zhang D, Dou X, et al. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol. 2018;6(1):1-10doi: 10.14218/JCTH.2017.00073.
Zhang, W., Zhang, D., Dou, X., Xie, Q., Jiang, J., Chen, X., & Ren, H. (2018). Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. Journal of clinical and translational hepatology, 6(1), 1-10. https://doi.org/10.14218/JCTH.2017.00073
Zhang, Wenhong, et al. "Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B." Journal of clinical and translational hepatology vol. 6,1 (2018): 1-10. doi: https://doi.org/10.14218/JCTH.2017.00073
Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X, Ren H. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol. 2018 Mar 28;6(1):1-10. doi: 10.14218/JCTH.2017.00073. Epub 2018 Mar 17. PMID: 29577026; PMCID: PMC5862993.
Copy Download .nbib Format: NLM
Chronic hepatitis B: Advances in treatment.

World journal of hepatology

Santantonio TA, Fasano M.
PMID: 24868322
World J Hepatol. 2014 May 27;6(5):284-92. doi: 10.4254/wjh.v6.i5.284.

Treatment of chronic hepatitis B (CHB) has markedly improved in the last 15 years due to the availability of direct antivirals which greatly increase therapeutic options. Currently, there are two classes of agents licensed for CHB treatment: standard or...

Cite
Santantonio TA, Fasano M. Chronic hepatitis B: Advances in treatment. World J Hepatol. 2014;6(5):284-92doi: 10.4254/wjh.v6.i5.284.
Santantonio, T. A., & Fasano, M. (2014). Chronic hepatitis B: Advances in treatment. World journal of hepatology, 6(5), 284-92. https://doi.org/10.4254/wjh.v6.i5.284
Santantonio, Teresa Antonia, and Fasano, Massimo. "Chronic hepatitis B: Advances in treatment." World journal of hepatology vol. 6,5 (2014): 284-92. doi: https://doi.org/10.4254/wjh.v6.i5.284
Santantonio TA, Fasano M. Chronic hepatitis B: Advances in treatment. World J Hepatol. 2014 May 27;6(5):284-92. doi: 10.4254/wjh.v6.i5.284. PMID: 24868322; PMCID: PMC4033286.
Copy Download .nbib Format: NLM
Variations in inflammatory genes are associated with periodontitis.

Immunity & ageing : I & A

Ianni M, Bruzzesi G, Pugliese D, Porcellini E, Carbone I, Schiavone A, Licastro F.
PMID: 24274085
Immun Ageing. 2013 Oct 01;10(1):39. doi: 10.1186/1742-4933-10-39.

BACKGROUND: Periodontitis is a multi-factorial disease and several risk-factors such as infections, inflammatory responses, oral hygiene, smoke, aging and individual predisposition are involved in the disease. Pathogens trigger chronic inflammation with cytokines release which in turn leads to the...

Cite
Ianni M, Bruzzesi G, Pugliese D, et al. Variations in inflammatory genes are associated with periodontitis. Immun Ageing. 2013;10(1):39doi: 10.1186/1742-4933-10-39.
Ianni, M., Bruzzesi, G., Pugliese, D., Porcellini, E., Carbone, I., Schiavone, A., & Licastro, F. (2013). Variations in inflammatory genes are associated with periodontitis. Immunity & ageing : I & A, 10(1), 39. https://doi.org/10.1186/1742-4933-10-39
Ianni, Manuela, et al. "Variations in inflammatory genes are associated with periodontitis." Immunity & ageing : I & A vol. 10,1 (2013): 39. doi: https://doi.org/10.1186/1742-4933-10-39
Ianni M, Bruzzesi G, Pugliese D, Porcellini E, Carbone I, Schiavone A, Licastro F. Variations in inflammatory genes are associated with periodontitis. Immun Ageing. 2013 Oct 01;10(1):39. doi: 10.1186/1742-4933-10-39. PMID: 24274085; PMCID: PMC3850543.
Copy Download .nbib Format: NLM
First reported case of interferon-alpha-induced sarcoidosis in an Asian patient with malignant melanoma.

Asia-Pacific journal of clinical oncology

Jeon EK, Hong J, Hong SH, Kang JY, Park G, Ahn MI, Lee JY, Kang J.
PMID: 24935527
Asia Pac J Clin Oncol. 2016 Jun;12(2):e347-e349. doi: 10.1111/ajco.12204. Epub 2014 Jun 17.

Anticancer agents can induce sarcoidosis. Interferon-alpha, which is used for the treatment of malignant melanoma and renal cell cancer, is one causative agent of sarcoidosis. However, there are few reports of interferon-alpha-induced sarcoidosis in patients with malignant melanoma. Clinically,...

Cite
Jeon EK, Hong J, Hong SH, et al. First reported case of interferon-alpha-induced sarcoidosis in an Asian patient with malignant melanoma. Asia Pac J Clin Oncol. 2014;12(2):e347-e349doi: 10.1111/ajco.12204.
Jeon, E. K., Hong, J., Hong, S. H., Kang, J. Y., Park, G., Ahn, M. I., Lee, J. Y., & Kang, J. (2016). First reported case of interferon-alpha-induced sarcoidosis in an Asian patient with malignant melanoma. Asia-Pacific journal of clinical oncology, 12(2), e347-e349. https://doi.org/10.1111/ajco.12204
Jeon, Eun Kyoung, et al. "First reported case of interferon-alpha-induced sarcoidosis in an Asian patient with malignant melanoma." Asia-Pacific journal of clinical oncology vol. 12,2 (2016): e347-e349. doi: https://doi.org/10.1111/ajco.12204
Jeon EK, Hong J, Hong SH, Kang JY, Park G, Ahn MI, Lee JY, Kang J. First reported case of interferon-alpha-induced sarcoidosis in an Asian patient with malignant melanoma. Asia Pac J Clin Oncol. 2016 Jun;12(2):e347-e349. doi: 10.1111/ajco.12204. Epub 2014 Jun 17. PMID: 24935527.
Copy Download .nbib Format: NLM
Autoantibodies in chronic hepatitis C: A clinical perspective.

World journal of hepatology

Narciso-Schiavon JL, Schiavon Lde L.
PMID: 26052396
World J Hepatol. 2015 May 18;7(8):1074-85. doi: 10.4254/wjh.v7.i8.1074.

Non-organ-specific autoantibodies and thyroid autoantibodies have been frequently found in chronic carriers of hepatitis C virus (HCV). With respect to endomysial antibodies and tissue transglutaminase, it is controversial whether the prevalence of gluten-related seromarkers is higher in patients with...

Cite
Narciso-Schiavon JL, Schiavon Lde L. Autoantibodies in chronic hepatitis C: A clinical perspective. World J Hepatol. 2015;7(8):1074-85doi: 10.4254/wjh.v7.i8.1074.
Narciso-Schiavon, J. L., & Schiavon, L. d. e. . L. (2015). Autoantibodies in chronic hepatitis C: A clinical perspective. World journal of hepatology, 7(8), 1074-85. https://doi.org/10.4254/wjh.v7.i8.1074
Narciso-Schiavon, Janaína Luz, and Schiavon, Leonardo de Lucca. "Autoantibodies in chronic hepatitis C: A clinical perspective." World journal of hepatology vol. 7,8 (2015): 1074-85. doi: https://doi.org/10.4254/wjh.v7.i8.1074
Narciso-Schiavon JL, Schiavon Lde L. Autoantibodies in chronic hepatitis C: A clinical perspective. World J Hepatol. 2015 May 18;7(8):1074-85. doi: 10.4254/wjh.v7.i8.1074. PMID: 26052396; PMCID: PMC4450184.
Copy Download .nbib Format: NLM
Management of hepatitis C virus infection in hemodialysis patients.

World journal of hepatology

Yu YC, Wang Y, He CL, Wang MR, Wang YM.
PMID: 25018852
World J Hepatol. 2014 Jun 27;6(6):419-25. doi: 10.4254/wjh.v6.i6.419.

The prevalence of hepatitis C virus (HCV) infection in patients on maintenance hemodialysis (MHD) is relatively higher than those without MHD. Chronic HCV infection detrimentally affects the life quality and expectancy, leads to renal transplant rejection, and increases the...

Cite
Yu YC, Wang Y, He CL, et al. Management of hepatitis C virus infection in hemodialysis patients. World J Hepatol. 2014;6(6):419-25doi: 10.4254/wjh.v6.i6.419.
Yu, Y. C., Wang, Y., He, C. L., Wang, M. R., & Wang, Y. M. (2014). Management of hepatitis C virus infection in hemodialysis patients. World journal of hepatology, 6(6), 419-25. https://doi.org/10.4254/wjh.v6.i6.419
Yu, Yue-Cheng, et al. "Management of hepatitis C virus infection in hemodialysis patients." World journal of hepatology vol. 6,6 (2014): 419-25. doi: https://doi.org/10.4254/wjh.v6.i6.419
Yu YC, Wang Y, He CL, Wang MR, Wang YM. Management of hepatitis C virus infection in hemodialysis patients. World J Hepatol. 2014 Jun 27;6(6):419-25. doi: 10.4254/wjh.v6.i6.419. PMID: 25018852; PMCID: PMC4081616.
Copy Download .nbib Format: NLM
Natural interferon-beta treatment for patients with chronic hepatitis C in Japan.

World journal of hepatology

Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O.
PMID: 26052401
World J Hepatol. 2015 May 18;7(8):1125-32. doi: 10.4254/wjh.v7.i8.1125.

Chronic hepatitis C virus (HCV) infection can cause liver cirrhosis and hepatocellular carcinoma (HCC). Several studies have demonstrated that the eradication of HCV reduces the occurrence of HCC. In Japan, as many people live to an advanced age, HCV-infected...

Cite
Sasaki R, Kanda T, Nakamoto S, et al. Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol. 2015;7(8):1125-32doi: 10.4254/wjh.v7.i8.1125.
Sasaki, R., Kanda, T., Nakamoto, S., Haga, Y., Nakamura, M., Yasui, S., Jiang, X., Wu, S., Arai, M., & Yokosuka, O. (2015). Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World journal of hepatology, 7(8), 1125-32. https://doi.org/10.4254/wjh.v7.i8.1125
Sasaki, Reina, et al. "Natural interferon-beta treatment for patients with chronic hepatitis C in Japan." World journal of hepatology vol. 7,8 (2015): 1125-32. doi: https://doi.org/10.4254/wjh.v7.i8.1125
Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O. Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol. 2015 May 18;7(8):1125-32. doi: 10.4254/wjh.v7.i8.1125. PMID: 26052401; PMCID: PMC4450189.
Copy Download .nbib Format: NLM
Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C.

NDT plus

Mimura I, Ishibashi Y, Tateishi R, Kaname S, Fujita T.
PMID: 25983890
NDT Plus. 2008 Aug;1(4):233-5. doi: 10.1093/ndtplus/sfn069. Epub 2008 Jun 05.

BACKGROUND: Although pegylated interferon (PEG-IFN) is now the standard treatment for chronic hepatitis C, there are few reports targeting dialysis patients and treatment protocol for hepatitis C virus (HCV) infection has not been determined, particularly in patients on peritoneal...

Cite
Mimura I, Ishibashi Y, Tateishi R, et al. Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C. NDT Plus. 2008;1(4):233-5doi: 10.1093/ndtplus/sfn069.
Mimura, I., Ishibashi, Y., Tateishi, R., Kaname, S., & Fujita, T. (2008). Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C. NDT plus, 1(4), 233-5. https://doi.org/10.1093/ndtplus/sfn069
Mimura, Imari, et al. "Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C." NDT plus vol. 1,4 (2008): 233-5. doi: https://doi.org/10.1093/ndtplus/sfn069
Mimura I, Ishibashi Y, Tateishi R, Kaname S, Fujita T. Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C. NDT Plus. 2008 Aug;1(4):233-5. doi: 10.1093/ndtplus/sfn069. Epub 2008 Jun 05. PMID: 25983890; PMCID: PMC4421225.
Copy Download .nbib Format: NLM
Life cycle and pathogenesis of hepatitis D virus: A review.

World journal of hepatology

Abbas Z, Afzal R.
PMID: 24409335
World J Hepatol. 2013 Dec 27;5(12):666-75. doi: 10.4254/wjh.v5.i12.666.

Hepatitis D virus (HDV) is a defective RNA virus which requires the help of hepatitis B virus (HBV) virus for its replication and assembly of new virions. HDV genome contains only one actively transcribed open reading frame which encodes...

Cite
Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus: A review. World J Hepatol. 2013;5(12):666-75doi: 10.4254/wjh.v5.i12.666.
Abbas, Z., & Afzal, R. (2013). Life cycle and pathogenesis of hepatitis D virus: A review. World journal of hepatology, 5(12), 666-75. https://doi.org/10.4254/wjh.v5.i12.666
Abbas, Zaigham, and Afzal, Rafia. "Life cycle and pathogenesis of hepatitis D virus: A review." World journal of hepatology vol. 5,12 (2013): 666-75. doi: https://doi.org/10.4254/wjh.v5.i12.666
Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus: A review. World J Hepatol. 2013 Dec 27;5(12):666-75. doi: 10.4254/wjh.v5.i12.666. PMID: 24409335; PMCID: PMC3879688.
Copy Download .nbib Format: NLM
Mixed Treatment Comparisons to Compare Simeprevir with Boceprevir and Telaprevir in Combination with Peg-Interferon Alpha and Ribavirin (Pr) in Patients Infected with Genotype 1 Hepatitis C Virus (Hcv).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Taieb V, Pacou M, Van Sanden S, Sbarigia U, Mehnert A, Duchesne I.
PMID: 27202427
Value Health. 2014 Nov;17(7):A665. doi: 10.1016/j.jval.2014.08.2450. Epub 2014 Oct 26.

No abstract available.

Cite
Taieb V, Pacou M, Van Sanden S, et al. Mixed Treatment Comparisons to Compare Simeprevir with Boceprevir and Telaprevir in Combination with Peg-Interferon Alpha and Ribavirin (Pr) in Patients Infected with Genotype 1 Hepatitis C Virus (Hcv). Value Health. 2014;17(7):A665doi: 10.1016/j.jval.2014.08.2450.
Taieb, V., Pacou, M., Van Sanden, S., Sbarigia, U., Mehnert, A., & Duchesne, I. (2014). Mixed Treatment Comparisons to Compare Simeprevir with Boceprevir and Telaprevir in Combination with Peg-Interferon Alpha and Ribavirin (Pr) in Patients Infected with Genotype 1 Hepatitis C Virus (Hcv). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A665. https://doi.org/10.1016/j.jval.2014.08.2450
Taieb, V, et al. "Mixed Treatment Comparisons to Compare Simeprevir with Boceprevir and Telaprevir in Combination with Peg-Interferon Alpha and Ribavirin (Pr) in Patients Infected with Genotype 1 Hepatitis C Virus (Hcv)." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A665. doi: https://doi.org/10.1016/j.jval.2014.08.2450
Taieb V, Pacou M, Van Sanden S, Sbarigia U, Mehnert A, Duchesne I. Mixed Treatment Comparisons to Compare Simeprevir with Boceprevir and Telaprevir in Combination with Peg-Interferon Alpha and Ribavirin (Pr) in Patients Infected with Genotype 1 Hepatitis C Virus (Hcv). Value Health. 2014 Nov;17(7):A665. doi: 10.1016/j.jval.2014.08.2450. Epub 2014 Oct 26. PMID: 27202427.
Copy Download .nbib Format: NLM
Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging.

Case reports in pediatrics

Keskindemirci G, Tuğcu D, Aydoğan G, Akçay A, Aktay Ayaz N, Er A, Yekeler E, Bilgiç B.
PMID: 26435870
Case Rep Pediatr. 2015;2015:537530. doi: 10.1155/2015/537530. Epub 2015 Sep 08.

Kasabach-Merritt phenomenon (KMP) is characterized by vascular tumour and consumptive coagulopathy with life-threatening thrombocytopenia, prolonged prothrombin time and partial thromboplastin time, hypofibrinogenemia, and the presence of high fibrin split products. We report a case of 3-year-old boy with local...

Cite
Keskindemirci G, Tuğcu D, Aydoğan G, et al. Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging. Case Rep Pediatr. 2015;2015:537530doi: 10.1155/2015/537530.
Keskindemirci, G., Tuğcu, D., Aydoğan, G., Akçay, A., Aktay Ayaz, N., Er, A., Yekeler, E., & Bilgiç, B. (2015). Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging. Case reports in pediatrics, 2015537530. https://doi.org/10.1155/2015/537530
Keskindemirci, Gonca, et al. "Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging." Case reports in pediatrics vol. 2015 (2015): 537530. doi: https://doi.org/10.1155/2015/537530
Keskindemirci G, Tuğcu D, Aydoğan G, Akçay A, Aktay Ayaz N, Er A, Yekeler E, Bilgiç B. Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging. Case Rep Pediatr. 2015;2015:537530. doi: 10.1155/2015/537530. Epub 2015 Sep 08. PMID: 26435870; PMCID: PMC4578750.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 848 entries